ANDA 218138, held by Pai Holdings Pharm. Lidocaine Hydrochloride.
As of Nov 16, 2026, ANDA 218138 (Lidocaine Hydrochloride Viscous), held by Pai Holdings Pharm, was first approved by FDA on Feb 20, 2024, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE: Lidocaine Hydrochloride Oral Topical Solution, USP 2% (Viscous) is indicated for the production of topical anesthesia of irritated or inflamed mucous membranes of the mouth and pharynx. It is also useful for reducing gagging during the taking of X-ray pictures and dental impressions.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 20, 2024 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Lidocaine Hydrochloride Viscous2% · solution;oral | Lidocaine Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters